CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Blood Adv. 2020 Aug 25;4(16):3850-3852. doi: 10.1182/bloodadvances.2020002587.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD19
  • Humans
  • Immunoconjugates*
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy

Substances

  • Antigens, CD19
  • Immunoconjugates